Heart Failure

Despite the most recent meta-analysis published this week in the British Medical Journal, digoxin use in atrial fibrillation remains limited.

The FDA is alerting health care professionals about serious adverse effects reported with implantable left ventricular assist devices (LVADs).

Within a few years of primary prevention defibrillator placement, one-quarter of heart failure (HF) patients show improvements in heart function above the clinical threshold.

Community pharmacists who expand their roles and make home visits to heart failure patients after hospital discharge can improve outcomes.

The entire July 2015 issue of Heart Failure Clinics is devoted to team-based care.

Warfarin remains a cornerstone anticoagulant for a number of reasons that include its low cost at the pharmacy counter.

The FDA is requiring all non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) to include strengthened label warnings describing how the painkillers increase the odds of heart attack or stroke.

Novartis's new heart failure drug, sacubitril and valsartan (Entresto), was recently approved by the FDA.

Moving away from the pay-per-pill standard, Novartis will attempt a new pricing model based on clinical outcomes for its widely anticipated chronic heart failure (HF) drug.

To win the health care relay race, one clinician needs to pass the baton to the next clinician, who must be ready to receive it.

High hospital readmission rates plague the health care system.

A study evaluating the cardiovascular safety of Merck's type 2 diabetes drug sitagliptin determined the dipeptidyl peptidase-4 inhibitor does not increase the risk for heart failure hospitalization.

Heart failure is a "revolving door" problem for hospitals.

Light or moderate alcohol intake has been associated with health benefits such as reduced risk of cardiovascular events, but these benefits disappear as intake increases.

Patients with heart failure often receive clopidogrel and angiotensin-converting enzyme inhibitors concurrently.

Of the 5.7 million Americans who have heart failure, about 10% progress to advanced Stage D.

A new prognostic model could help clinicians prioritize risk factors in heart failure patients.

Thiazide diuretics are the least expensive antihypertensive drugs available in most countries.

Americans make many assumptions about aging, and health care providers are no exception.

Today's approval of Amgen's ivabradine makes it the first new chronic heart failure medicine that has been approved by the FDA in almost a decade.

An FDA advisory panel recommends adding a warning about the potential risk for heart failure to the labels of saxagliptin (Onglyza), saxagliptin/metformin (Kombiglyze), and alogliptin (Nesina).

Pharmacists can improve a patient's medication adherence by dispensing information beyond a drug's label.

Readmission rates among patients with heart failure, acute myocardial infarction, and pneumonia increase when psychiatric illness is also present.

Veterans with post-traumatic stress disorder face greater odds of developing heart failure.

The FDA recently granted priority review to Novarits' investigational drug LCZ696, a potential treatment for heart failure with ejection fraction.